Venous Stenting Evaluation in Patients With Intracranial Hypertension Under Long-term Acetazolamide

NCT ID: NCT06945848

Last Updated: 2025-04-25

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 114 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-04-30
• Study Completion Date: 2029-04-30

Brief Summary

This study is aimed at patients suffering from long term intracranial hypertension (caracterized by visual loss, chronic headache and/or tinnitus), receiving acetazolamide for more than 1 year, having inadequate response to treatment (untolerable side effects or insufficient efficacy).

The goal is to evaluate if stenting of a specific vein in the brain could decrease the hypertension and improve associated symptoms. Patients will be randomly assigned in either best medical care group (recommended medication associated with weight loss) or interventional group (best medical care + stenting of the specific vein) and will undergo specific follow-up visits after 1, 3 and 12 months.

Detailed Description

The DIVE-IIN-LATE trial is a multicenter randomized controlled trial designed to evaluate whether transverse sinus stenting is more effective than best medical therapy alone for patients with idiopathic intracranial hypertension (IIH) treated with acetazolamide for more than one year. The study targets patients diagnosed with IIH with bilateral transverse sinus stenosis or unilateral stenosis of the dominant transverse sinus with a hypoplastic contralateral sinus.

Idiopathic intracranial hypertension is, in most cases, associated with narrowing of the transverse sinus vein, which may be the cause of increased intracranial blood pressure, resulting in the accumulation and increase in intracranial fluid pressure. This increased pressure is thought to be responsible for papilledema, chronic headaches, and tinnitus, among other symptoms.

Restoring a normal luminal diameter of the transverse sinus using a stent could therefore allow for the rapid restoration of normal intracranial pressures and an improvement in various symptoms.

Stent implantation in the transverse sinus is now part of standard care, but no large-scale clinical trial has formally established the superiority of the technique compared to the standard of care (drug therapy combined with weight loss). This study aims to provide evidence on the potential benefits of transverse venous sinus stenting as a treatment option for patients with idiopathic intracranial hypertension, which could significantly change the current management approach of this disease.

Conditions

Idiopathic Intracranial Hypertension (IIH)

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Acetazolamide

Acetazolamide and recommended weight loss

Group Type: ACTIVE_COMPARATOR

Acetazolamide

Intervention Type: DRUG

Acetazolamide will be maintained and weight loss will be recommended

Experimental (stenting, neuro-radiological intervention)

Stenting of the transverse sinus vein

Group Type: EXPERIMENTAL

Stent (Tentos 4F or Precise ProRX)

Intervention Type: DEVICE

Transverse venous sinus will be stented by neuroradiological intervention

Interventions

Acetazolamide

Acetazolamide will be maintained and weight loss will be recommended

Intervention Type: DRUG

Stent (Tentos 4F or Precise ProRX)

Transverse venous sinus will be stented by neuroradiological intervention

Intervention Type: DEVICE

Other Intervention Names

Weight loss

Eligibility Criteria

Inclusion Criteria

1. Subject is ≥ 18 years old at inclusion.

2. Subject with definite diagnosis of IIH satisfying the modified Dandy criteria (A to E) ) at the time of initial diagnosis, under BMM including ACZ for more than 1 year

3. Patient with elevated intracranial pressure defined as > 25 cm H20 or 18 mmHg

4. Subject with intracranial TVS stenosis on dominant transverse sinus and hypoplastic contralateral one (or bilateral TVS stenosis) diagnosed on MRI

5. Normal MRI findings excepted intracranial TVS stenosis or IIH related abnormalities

6. Patient having received information about data collection and having signed and dated an Informed Consent Form

7. Subjects must be able to attend all scheduled visits and to comply with all trial procedures

8. Subjects must be covered by public health insurance

Exclusion Criteria

1. Patients receiving topiramate in the previous month

2. Known contrast product, Nickel, titanium allergy

3. Exposure to an oral drug (other than ACZ), substance, or disorder that has been associated with elevation of intracranial pressure within 2 months of diagnosis (lithium, vitamin A, tetracycline and related compounds)

4. History of intracranial venous thrombosis or intracranial neoplasia

5. Fulminant decrease of visual acuity due to the IIH defined as a visual loss (of the most seriously impaired eye) of at least 3/10 (from corrected vision) within 4 weeks, in absence of any other ophthalmologic pathology and Mean Deficit of visual field superior to -10 dB

6. Optic nerve atrophy

7. Amblyopia

8. Refractive error greater ±8 sphere or more than ±3 in cylinder in either eye if there are abnormalities in funduscopy (optic disc tilt, staphyloma), previous glaucoma, other disorders causing visual loss

9. Pregnancy: if a woman is of childbearing potential a urine or serum beta HCG test is positive

10. Patient with a severe or fatal comorbidity that will likely prevent improvement or follow-up or that will render the procedure unlikely to benefit the patient.

11. Evidence of intracranial hemorrhage (subarachnoid hemorrhage (SAH), intracerebral hemorrhage (ICH), etc.)

12. Life expectancy under 6 months

13. Patients with renal failure (creatinine > 1.5 mg/dl and/or creatinine clearance < 60 mL/min, except if patient is already on hemodialysis)

14. History of previously implanted intra-cranial sinus stent

15. Previous gastric bypass surgery AAP-DGOS PHRC-N 22_0175 CHU DE MONTPELLIER Pr Costalat Vincent/Pr Ducros Anne Version n°2.2 date 25/03/2025 Page 28 sur 63

16. Contra-indication to general anesthesia

17. Contra-indication to aspirin, clopidogrel or other P2Y12 anti-aggregant

18. History of chronic obstructive pulmonary disease or other severe respiratory disease

19. History of deep vein thrombosis or pulmonary embolism

20. History of atrial fibrillation or other risks of stroke

21. Cerebral vascular lesions (arteriovenous malformation, arteriovenous fistula, aneurysms, significant stenosis of extra- or intra-cranial vessels other than the targeted venous sinus stenosis, intracranial artery dissection, etc.).

22. Anatomical anomaly of the venous sinus which would prevent safe catheterization and stenting

23. Subject who are in a dependency or employment with the sponsor or the investigator

24. Participation in another clinical trial or administration of an unapproved drug within the last 4 weeks before the screening date

25. Subject protected according to the French Public Health Code (e.g. patients under law protection, prisoners, pregnant, parturient or lactating women, and patients under guardianship/curatorship)

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Direction Générale de l'Offre de Soins

OTHER_GOV

Sponsor Role: collaborator

University Hospital, Montpellier

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Vincent COSTALAT, MD, PhD

Role: STUDY_DIRECTOR

University hospital of Montpellier, FRANCE

Locations

CHU de Montpellier Hôpital Gui de Chauliac

Montpellier, , France

CHU de Reims

Reims, , France

CHU de Toulouse

Toulouse, , France

Countries

France

Central Contacts

Vincent COSTALAT, MD, PhD

Role: CONTACT

v-costalat@chu-montpellier.fr

+33 467 337 532

Fédérico CAGNAZZO, MD, PhD

Role: CONTACT

f-cagnazzo@chu-montpellier.fr

+33 467 337 532

Facility Contacts

Vincent COSTALAT, MD, PhD

Role: primary

v-costalat@chu-montpellier.fr

+33 467 337 532

Sébastien SOIZE, MD, PhD

Role: primary

ssoize@chu-reims.fr

+33 326 788 764

Guillaume BELLANGER, MD, PhD

Role: primary

bellanger.g@chu-toulouse.fr

+33 561 772 339

Other Identifiers

IDRCB

Identifier Type: OTHER

Identifier Source: secondary_id

RECHMPL 23_0410

Identifier Type: -

Identifier Source: org_study_id